Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors

3 Apr 2023

Abstract excerpt

BACKGROUND: Multiple preclinical studies have shown cytotoxic synergy involving combinations of poly (ADP-ribose) polymerase (PARP) inhibitors and topoisomerase 1 (TOP1) inhibitors, but such combinations have proven too toxic in clinical trials. Liposomal irinotecan (nal-IRI) achieved similar intratumoral exposure with better antitumor activity than the conventional TOP1 inhibitor irinotecan in preclinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37010988
DOI: 10.1093/oncolo/oyad023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsPMID 37010988Read ↗

Profile of veliparib and its potential in the treatment of solid tumorsSemantic proximity Read ↗

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.Semantic proximity Read ↗

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

An Open Label, Pilot Study of Veliparib and Lapatinib in Patients with Metastatic, Triple Negative Breast CancerSemantic proximity Read ↗

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.Semantic proximity Read ↗

Rationale and clinical use of multitargeting anticancer agentsSemantic proximity Read ↗

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.Semantic proximity Read ↗

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.Semantic proximity Read ↗

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Semantic proximity Read ↗

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Semantic proximity Read ↗

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.